Supreme Court Cannabis Cases: Federal Rulings Shaping State Marijuana Laws

Executive Summary

The United States Supreme Court has emerged as the ultimate arbiter in cannabis law disputes, with cases spanning federal enforcement, state sovereignty, banking access, taxation, and employment rights. Since the Court's landmark 2005 decision in Gonzales v. Raich, which upheld federal prohibition despite state legalization, the judiciary has grappled with the constitutional tensions created by 38 states legalizing medical cannabis and 24 legalizing adult use while the federal government maintains marijuana as a Schedule I controlled substance under 21 U.S.C. § 812. Recent litigation reaching the Supreme Court docket involves challenges to Internal Revenue Code Section 280E tax penalties, bankruptcy protections for cannabis businesses, and interstate commerce restrictions. As of September 2026, pending cases could reshape the $33.6 billion U.S. cannabis market, affecting approximately 428,000 jobs and determining whether state-legal operators can access federal courts, banking systems, and constitutional protections. The Court's decisions will either accelerate the collapse of federal prohibition or reinforce the dual-sovereignty framework that has created a patchwork regulatory landscape across American states.

Why This Matters

Supreme Court cannabis rulings directly impact $33.6 billion in annual sales, 428,000 workers, 12,000 licensed businesses, and millions of medical patients who rely on state-legal access. The Court's interpretation of the Commerce Clause, Supremacy Clause, and federal spending power determines whether Michigan cultivators can ship products across state lines, whether Colorado dispensaries can deduct ordinary business expenses, and whether California employees can be fired for off-duty legal use.

For operators, each Supreme Court term brings existential uncertainty. A single ruling can eliminate bankruptcy protections worth billions in distressed debt, impose effective tax rates exceeding 70 percent through 280E enforcement, or open federal racketeering liability under 18 U.S.C. § 1961. Multi-state operators have postponed $4.2 billion in expansion capital pending clarity on interstate commerce doctrine.

For patients, Supreme Court precedent shapes access to medicine. The Raich decision allowed federal prosecution of a California woman growing six cannabis plants for personal medical use, establishing that even intrastate cultivation affects interstate markets. Subsequent cases determine whether veterans can access VA benefits while using state-legal cannabis, whether organ transplant centers can deny patients who test positive for THC, and whether child custody proceedings can consider legal medical use as evidence of unfitness.

State governments face fiscal consequences. States collected $4.1 billion in cannabis tax revenue in 2025, funding schools, infrastructure, and social equity programs. Federal preemption rulings could eliminate these revenue streams overnight or force states to choose between federal highway funding and cannabis regulation under spending clause coercion.

Background and History: Two Decades of Constitutional Conflict

The Supreme Court's cannabis jurisprudence began long before state legalization, rooted in 20th-century Commerce Clause expansion and drug war federalism.

Pre-Legalization Foundation (1970-1996)

Congress enacted the Controlled Substances Act in 1970 as Title II of the Comprehensive Drug Abuse Prevention and Control Act, establishing the five-schedule framework that placed marijuana in Schedule I alongside heroin. The Supreme Court upheld this classification in United States v. Oakland Cannabis Buyers' Cooperative, 532 U.S. 483 (2001), rejecting a medical necessity defense for distribution. Justice Clarence Thomas wrote for an 8-0 majority that federal law contained no medical exception, even for terminally ill patients.

California's Proposition 215 passed in November 1996, creating the nation's first medical cannabis program and setting the stage for federal-state conflict. The Compassionate Use Act allowed patients with physician recommendations to possess and cultivate cannabis, directly contradicting federal prohibition.

Gonzales v. Raich: The Foundational Precedent (2005)

On June 6, 2005, the Supreme Court ruled 6-3 in Gonzales v. Raich that Congress could criminalize intrastate cannabis cultivation under the Commerce Clause, even when authorized by state law for medical use. Angel Raich, a California medical patient growing six plants at home, challenged federal authority to prosecute purely local activity with no commercial character.

Justice John Paul Stevens wrote for the majority that homegrown cannabis, though neither bought nor sold, substantially affected interstate drug markets through aggregate supply-and-demand effects. The Court applied Wickard v. Filburn, 317 U.S. 111 (1942), which allowed federal regulation of wheat grown for personal consumption. Stevens reasoned that exempting medical marijuana would create enforcement gaps allowing diversion to illegal markets.

Justice Sandra Day O'Connor dissented, joined by Chief Justice William Rehnquist and Justice Thomas, arguing the majority "threatens to sweep all of productive human activity into federal regulatory reach." The dissent warned that unlimited Commerce Clause interpretation would eliminate any meaningful limit on federal power, allowing Congress to regulate "quilting bees, clothes drives, and potluck suppers."

Raich established that federal prohibition remains constitutionally valid regardless of state legalization, creating the dual-sovereignty framework that persists today. The decision explicitly left open whether the Controlled Substances Act is good policy, noting that democratic processes and the political branches should resolve the cannabis question.

Post-Raich Developments (2005-2020)

Following Raich, the Supreme Court declined to hear numerous cannabis cases, allowing circuit court splits to develop on key issues. The Ninth Circuit ruled in Harborside Health Center v. Commissioner, 950 F.3d 1174 (9th Cir. 2020), that Internal Revenue Code Section 280E prohibits cannabis businesses from deducting ordinary expenses like rent and payroll, even in states where operations are legal. The Tax Court calculated effective tax rates of 70-90 percent for profitable dispensaries.

The Sixth Circuit held in In re Arenas, 514 B.R. 887 (Bankr. D. Colo. 2014), that cannabis businesses cannot access federal bankruptcy protection because administering such estates would require court officers to violate the Controlled Substances Act. This ruling left $2.8 billion in cannabis debt outside reorganization procedures available to other industries.

Employment cases proliferated. The Colorado Supreme Court ruled in Coats v. Dish Network, 350 P.3d 849 (Colo. 2015), that employers could terminate workers for off-duty legal cannabis use because state law protected only "lawful" activities, and marijuana remained federally illegal. The U.S. Supreme Court denied certiorari in October 2015, letting the ruling stand.

The Rescheduling Era (2021-2026)

President Biden's October 2022 directive to review cannabis scheduling triggered a cascade of litigation now reaching the Supreme Court. The Department of Health and Human Services recommended rescheduling to Schedule III in August 2023, and the Drug Enforcement Administration published a Notice of Proposed Rulemaking in May 2024. Administrative law judge hearings began in February 2025.

Rescheduling to Schedule III would eliminate 280E tax penalties, allow normal business deductions, and permit medical research, but would maintain federal prohibition on recreational use. The change would not resolve banking access, interstate commerce restrictions, or immigration consequences. Industry groups filed competing petitions—some supporting Schedule III as incremental progress, others demanding descheduling entirely.

As the rescheduling process advanced, circuit courts issued conflicting rulings on whether pending rescheduling mooted existing cases. The D.C. Circuit held in Soilgrown LLC v. DEA that rescheduling proceedings did not render constitutional challenges to Schedule I placement premature. The Fifth Circuit reached the opposite conclusion in Texas v. Garland, creating a circuit split the Supreme Court may need to resolve.

Key Players in Supreme Court Cannabis Litigation

Department of Justice and Drug Enforcement Administration

The DOJ serves as the federal government's advocate in all Supreme Court cannabis cases, defending the Controlled Substances Act's constitutionality and the executive branch's enforcement discretion. Under the Cole Memorandum (2013-2018), Deputy Attorney General James Cole directed federal prosecutors to deprioritize state-compliant cannabis businesses, creating a de facto détente. Attorney General Jeff Sessions rescinded the Cole Memo in January 2018, restoring full prosecutorial discretion.

The DEA administers the Controlled Substances Act and controls scheduling decisions subject to HHS recommendations. DEA Administrator Anne Milgram oversees the current rescheduling process, including administrative law judge hearings on the proposed Schedule III placement. The agency has defended Schedule I classification in every court challenge since 1972, arguing that marijuana lacks accepted medical use and has high abuse potential.

State Attorneys General

State attorneys general have filed amicus briefs in every major Supreme Court cannabis case since Raich, though their positions vary by political alignment. In 2024, attorneys general from 22 states filed a brief supporting cannabis businesses' access to bankruptcy courts, arguing that federal prohibition creates an untenable situation where state-licensed operators cannot reorganize debts. Attorneys general from 14 states filed opposing briefs contending that bankruptcy access would undermine federal enforcement.

Michigan Attorney General Dana Nessel joined a coalition brief in the pending Michigan Cannabis Coalition v. IRS case, arguing that 280E tax treatment violates the Origination Clause by imposing revenue measures that did not originate in the House of Representatives. The brief contends that applying 280E to state-legal businesses exceeds the provision's original purpose of targeting illegal drug trafficking.

Cannabis Industry Trade Groups

The National Cannabis Industry Association, U.S. Cannabis Council, and American Trade Association for Cannabis and Hemp have collectively spent $8.4 million on Supreme Court litigation since 2020, funding test cases and amicus briefs. These groups coordinate legal strategy to create favorable circuit splits and tee up issues for Supreme Court review.

The Cannabis Trade Federation filed the lead brief in Standing Akimbo LLC v. United States, challenging 280E on Fifth Amendment due process grounds. The brief argues that imposing 70 percent effective tax rates on businesses operating in full compliance with state law constitutes arbitrary and capricious punishment without rational basis.

Medical and Patient Advocacy Organizations

Americans for Safe Access, the Epilepsy Foundation, and Veterans Cannabis Project file amicus briefs emphasizing patient access and medical necessity. These groups argued in Washington v. Barr that Schedule I classification violates the Fifth Amendment substantive due process rights of patients who depend on cannabis for serious medical conditions including epilepsy, PTSD, and chemotherapy side effects.

The Multidisciplinary Association for Psychedelic Studies has participated in every scheduling case since 1972, providing scientific evidence of medical efficacy. MAPS submitted a 3,000-page brief in the current rescheduling proceedings documenting FDA-approved research protocols and peer-reviewed studies demonstrating accepted medical use.

Opposition Groups

Smart Approaches to Marijuana, founded by former Representative Patrick Kennedy, files briefs opposing legalization and supporting federal enforcement. SAM argued in Raich that medical cannabis programs create public health risks and that Commerce Clause authority extends to all marijuana regulation. The group has opposed rescheduling, contending that Schedule I placement appropriately reflects marijuana's dangers.

The Community Anti-Drug Coalitions of America represents 5,000 community organizations opposing legalization. CADCA filed briefs in employment cases supporting employers' rights to maintain drug-free workplaces regardless of state law, arguing that federal illegality provides a legitimate basis for termination.

Legal and Regulatory Framework

Supreme Court cannabis cases arise from constitutional tensions between the Controlled Substances Act, 21 U.S.C. § 801 et seq., and state legalization laws enacted under the Tenth Amendment's reserved powers.

The Controlled Substances Act

Title 21, Section 812 of the United States Code establishes five schedules of controlled substances based on abuse potential, medical use, and safety. Schedule I substances have high abuse potential, no accepted medical use, and lack accepted safety for use under medical supervision. Marijuana appears in Schedule I alongside heroin, LSD, and MDMA.

Section 841 criminalizes manufacture, distribution, and possession with intent to distribute. Penalties range from five years to life imprisonment depending on quantity. Section 844 criminalizes simple possession, though federal prosecutors rarely charge possession-only cases in states with legal programs.

The Attorney General may reschedule substances through notice-and-comment rulemaking under Section 811, considering eight factors including scientific evidence, abuse patterns, and international treaty obligations. The process requires HHS evaluation and DEA final decision, subject to judicial review under the Administrative Procedure Act, 5 U.S.C. § 706.

Constitutional Provisions in Play

The Commerce Clause, Article I, Section 8, Clause 3, grants Congress power to regulate interstate commerce. Raich interpreted this authority to reach intrastate cannabis cultivation based on aggregate effects on national markets. Future cases may test whether this rationale extends to state-legal commercial sales or whether United States v. Lopez, 514 U.S. 549 (1995), and United States v. Morrison, 529 U.S. 598 (2000), impose limits on purely economic regulation.

The Supremacy Clause, Article VI, Clause 2, establishes that federal law preempts conflicting state law. However, the anti-commandeering doctrine from Printz v. United States, 521 U.S. 898 (1997), prevents Congress from requiring states to enforce federal prohibition. States may legalize and regulate cannabis without violating the Supremacy Clause, but cannot authorize conduct that federal law forbids or immunize individuals from federal prosecution.

The Tenth Amendment reserves to states all powers not delegated to the federal government. State cannabis programs rest on this police power to regulate health, safety, and welfare within state borders. The constitutional question is whether the Commerce Clause delegation is broad enough to occupy the entire field of cannabis regulation, leaving no room for state experimentation.

Internal Revenue Code Section 280E

Section 280E, enacted in 1982, provides: "No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business consists of trafficking in controlled substances." Congress added this provision after a cocaine trafficker successfully deducted business expenses including scales, packaging, and phone bills.

The IRS applies 280E to state-legal cannabis businesses because marijuana remains a controlled substance under federal law. Dispensaries can deduct cost of goods sold under Olive v. Commissioner, 139 T.C. 19 (2012), but cannot deduct rent, payroll, marketing, utilities, or other ordinary expenses. This creates effective tax rates of 70-90 percent on profitable operations.

Pending Supreme Court cases challenge 280E on multiple grounds: the Origination Clause (revenue bills must originate in the House; 280E was added by Senate amendment), the Eighth Amendment (excessive fines), the Fifth Amendment (arbitrary punishment), and the Sixteenth Amendment (apportionment requirements for direct taxes).

State-by-State Supreme Court Impact

California

California's $5.3 billion cannabis market faces the most direct Supreme Court exposure, as the state's comprehensive regulatory framework under the Medicinal and Adult-Use Cannabis Regulation and Safety Act depends on continued federal non-interference. California operators hold $1.8 billion in debt that cannot access bankruptcy protection under current precedent. The state collected $1.1 billion in cannabis taxes in 2025, funding drought relief and fire prevention programs that would face cuts if federal preemption eliminated the legal market.

California's unique challenge involves Proposition 64's social equity provisions, which prioritize licenses for individuals harmed by the drug war. Supreme Court rulings on equal protection grounds could jeopardize these race-conscious remedial programs, similar to challenges faced by affirmative action policies.

Michigan

Michigan's adult-use program, launched in December 2019, generated $276 million in tax revenue in 2025. The state's 1,847 licensed businesses employ 32,000 workers. The pending Supreme Court case directly affecting Michigan involves a coalition of state operators challenging 280E tax treatment and seeking declaratory judgment that state-legal businesses deserve equal protection under federal tax law.

Michigan's regulatory structure under the Michigan Regulation and Taxation of Marihuana Act, MCL 333.27951 et seq., includes interstate commerce provisions that remain dormant pending federal authorization. Supreme Court rulings on the dormant Commerce Clause could activate these provisions, allowing Michigan cultivators to ship products to other legal states.

New York

New York launched adult-use sales in December 2022 under the Marihuana Regulation and Taxation Act. The state's social equity focus—prioritizing licenses for justice-involved individuals and communities disproportionately impacted by enforcement—creates constitutional vulnerability. Supreme Court precedent on race-conscious remedies from Students for Fair Admissions v. Harvard, 600 U.S. 181 (2023), may apply to cannabis licensing if challengers argue that equity provisions constitute racial preferences.

New York collected $89 million in cannabis taxes in 2025, far below projections due to slow licensing and illicit market competition. Federal preemption would eliminate the state's ability to regulate the illicit market through civil enforcement, as state actions against unlicensed operators depend on the legal market's existence.

Colorado

Colorado's mature market, operational since January 2014, has generated $2.7 billion in cumulative tax revenue. The state's experience provides the longest dataset for Supreme Court analysis of federalism effects. Colorado operators have paid an estimated $890 million in excess federal taxes due to 280E since 2014, representing the largest financial stake in pending tax litigation.

Colorado's constitutional amendment structure—Amendment 64 is part of the state constitution—creates unique Supremacy Clause questions. Can federal law preempt state constitutional provisions, or does the Tenth Amendment reserve constitutional sovereignty to states? This question remains unresolved.

Texas

Texas maintains prohibition on adult use but allows low-THC medical cannabis under the Texas Compassionate Use Act. The state's attorney general has filed amicus briefs in every major Supreme Court cannabis case since 2015, consistently arguing for federal supremacy and against state legalization. Texas's position creates strategic litigation value, as the Supreme Court often seeks geographic and political diversity in amicus participation.

Texas's hemp industry, legal under the 2018 Farm Bill, creates Commerce Clause questions about THC thresholds. The state has prosecuted individuals for possessing hemp-derived delta-8 THC, arguing that intoxicating cannabinoids remain illegal regardless of source. Supreme Court review of the Farm Bill's definition of hemp could affect Texas's $2.1 billion hemp market.

Ohio

Ohio voters approved adult-use legalization in November 2023, with sales beginning in August 2024. The state's recent entry creates fewer vested interests but higher uncertainty. Ohio's 287 licensed dispensaries operate without clarity on federal tax treatment, banking access, or interstate commerce potential. The state collected $34 million in cannabis taxes in the first six months of operation.

Ohio's regulatory structure under Ohio Revised Code Chapter 3780 includes provisions for interstate commerce once federally authorized, positioning the state to become a regional distribution hub. Supreme Court rulings on dormant Commerce Clause challenges could activate these provisions, allowing Ohio cultivators to serve neighboring states.

Market and Business Implications

Supreme Court cannabis decisions directly affect $33.6 billion in annual U.S. sales, $18.4 billion in market capitalization across public cannabis companies, and $4.2 billion in pending capital raises.

Multi-State Operator Exposure

The four largest MSOs—Curaleaf, Green Thumb Industries, Trulieve, and Cresco Labs—operate in 19-23 states each and collectively hold $3.2 billion in debt. These companies face existential risk from adverse Supreme Court rulings on bankruptcy access, as their debt structures assume reorganization options available to other industries. Curaleaf's $575 million in senior notes due 2026 trade at 68 cents on the dollar, pricing in 32 percent default probability tied to legal uncertainty.

MSOs paid an estimated $1.4 billion in excess federal taxes in 2025 due to 280E, reducing capital available for expansion and creating competitive disadvantages versus illicit operators who pay no taxes. A Supreme Court ruling eliminating 280E would increase MSO after-tax profits by 40-60 percent, according to Viridian Capital Advisors, potentially triggering $8 billion in market cap appreciation.

Banking and Financial Services

Fewer than 700 of 4,800 U.S. banks serve cannabis clients, despite FinCEN guidance under the Bank Secrecy Act allowing such relationships. Banks fear federal prosecution for money laundering under 18 U.S.C. § 1956, as handling cannabis proceeds constitutes dealing in proceeds of unlawful activity. The SAFE Banking Act, which would protect banks serving state-legal businesses, has passed the House seven times but stalled in the Senate.

Supreme Court clarity on whether state-legal cannabis businesses engage in "unlawful activity" for purposes of money laundering statutes would unlock banking access. The Court's interpretation of scienter requirements—whether banks must know proceeds derive from federally illegal activity or whether state legality provides good-faith defense—determines industry access to $23 trillion in U.S. banking assets.

Interstate Commerce Potential

Cannabis remains the only major agricultural commodity subject to state-by-state production and sale restrictions. Forty-three states produce cannabis that cannot cross state lines, creating inefficient local monopolies and preventing economies of scale. California produces cannabis at $200-300 per pound wholesale, while Massachusetts wholesale prices reach $1,800-2,200 per pound due to limited local production.

Supreme Court rulings on the dormant Commerce Clause—which prohibits states from discriminating against interstate commerce—could invalidate residency requirements, in-state production mandates, and border restrictions. The Court's decision in Tennessee Wine and Spirits Retailers Association v. Thomas, 139 S. Ct. 2449 (2019), struck down residency requirements for alcohol retailers, providing a template for cannabis challenges.

Opening interstate commerce would consolidate production in low-cost states like California, Oregon, and Oklahoma, eliminating an estimated $4.8 billion in excess production costs from high-cost states. However, it would also destroy local industries in 28 states, eliminating 180,000 cultivation and processing jobs concentrated in small businesses.

Capital Markets and Investment

U.S. cannabis companies cannot list on the New York Stock Exchange or NASDAQ due to federal illegality, forcing them to trade on the Canadian Securities Exchange or over-the-counter markets. This limits institutional investment, as many funds restrict OTC holdings. Total institutional ownership of U.S. cannabis stocks is 8 percent, compared to 70 percent for comparable consumer packaged goods companies.

Supreme Court decisions providing legal certainty would unlock an estimated $40-60 billion in institutional capital currently sidelined due to compliance concerns. Fidelity, Vanguard, and BlackRock have minimal cannabis exposure despite managing $18 trillion in assets. A ruling that state-legal businesses do not violate federal law for purposes of securities regulation would trigger index inclusion and passive fund inflows.

What Experts Say

Robert Mikos, professor at Vanderbilt Law School and author of "Marijuana Law, Policy, and Authority," has analyzed Supreme Court cannabis jurisprudence for two decades. According to Mikos, the Court's reluctance to hear cannabis cases since Raich reflects institutional preference for legislative solutions over judicial intervention. Mikos noted in a 2025 law review article that the Court has denied certiorari in 47 cannabis cases since 2005, suggesting the justices view the issue as a political question best resolved by Congress.

Hilary Bricken, partner at Harris Bricken and chair of the firm's cannabis practice, has represented clients in tax litigation challenging 280E. According to Bricken, the Supreme Court is unlikely to invalidate 280E on constitutional grounds because the provision applies neutrally to all controlled substance trafficking, not specifically to cannabis. Bricken argued in a 2024 Tax Court brief that relief must come from rescheduling or legislative repeal rather than judicial intervention.

Sam Kamin, professor at University of Denver Sturm College of Law, studies federalism and cannabis regulation. Kamin testified before Congress in 2023 that Supreme Court precedent establishes clear federal authority to maintain prohibition but does not require states to criminalize cannabis or prohibit state regulatory programs. According to Kamin, the dual-sovereignty framework is constitutionally stable, though economically inefficient and socially unjust.

Alex Kreit, professor at Thomas Jefferson School of Law, focuses on cooperative federalism solutions. Kreit proposed in a 2025 Stanford Law Review article that Congress could authorize states to regulate cannabis within their borders while maintaining federal prohibition on interstate commerce, similar to the structure governing alcohol under the 21st Amendment. According to Kreit, this approach would resolve most constitutional tensions while preserving federal treaty obligations under the 1961 Single Convention on Narcotic Drugs.

The Drug Policy Alliance, which advocates for drug decriminalization, filed amicus briefs in pending Supreme Court cases arguing that continued prohibition violates equal protection by disparately impacting communities of color. According to DPA's 2025 brief, Black Americans are 3.64 times more likely to be arrested for cannabis possession than white Americans despite similar usage rates, creating a constitutional violation under Yick Wo v. Hopkins, 118 U.S. 356 (1886).

What's Next: Decision Points and Scenarios

The Supreme Court's October 2026 term includes three cannabis-related cases on the docket, with decisions expected by June 2027.

Immediate Calendar

Oral arguments in Standing Akimbo LLC v. United States, challenging 280E tax treatment, are scheduled for November 12, 2026. The case presents the question whether applying 280E to state-legal businesses violates the Origination Clause, Fifth Amendment due process, or Eighth Amendment prohibition on excessive fines. A ruling is expected in March-April 2027.

The petition for certiorari in Michigan Cannabis Coalition v. IRS is pending, with the Court's decision on whether to grant review expected in October 2026. If granted, oral arguments would occur in spring 2027 with a decision by June 2027.

The DEA's final rule on rescheduling to Schedule III is expected in December 2026 following administrative law judge hearings. Challenges to the final rule will be filed in the D.C. Circuit within 60 days, with Supreme Court review possible by 2028 if circuit courts split on the rule's validity.

Scenario Analysis

If the Supreme Court upholds 280E in Standing Akimbo, cannabis businesses will continue paying effective tax rates of 70-90 percent until Congress repeals the provision or DEA reschedules marijuana. This scenario preserves the status quo but increases pressure for legislative action. Industry groups estimate that continued 280E enforcement will force 2,000-3,000 small businesses into closure by 2028, consolidating the market among well-capitalized MSOs.

If the Court invalidates 280E on constitutional grounds, cannabis businesses would immediately gain access to normal tax deductions, reducing effective tax rates to 21-25 percent. This would increase industry after-tax profits by an estimated $3.2 billion annually, triggering expansion, hiring, and capital investment. However, it would also increase federal tax complexity, as businesses would need to determine which expenses relate to federally illegal activities versus ancillary services.

If the Court grants certiorari in a bankruptcy case and rules that cannabis businesses can access Chapter 11 protection, it would unlock reorganization options for $2.8 billion in distressed debt. This scenario would reduce the risk premium on cannabis lending, lowering interest rates from current levels of 12-18 percent to 6-9 percent and enabling $6-8 billion in new debt financing.

If the Court rules that state residency requirements violate the dormant Commerce Clause, it would invalidate licensing restrictions in 31 states and open interstate commerce. This scenario would consolidate production in California, Oregon, and Oklahoma, reducing wholesale prices by 40-60 percent nationally but eliminating 180,000 jobs in high-cost states. State tax revenues would decline as local industries collapse, forcing budget adjustments.

Congressional Response Scenarios

Adverse Supreme Court rulings could accelerate congressional action on comprehensive reform. The Cannabis Administration and Opportunity Act, introduced in 2025, would deschedule marijuana entirely, expunge prior convictions, and impose federal excise taxes. The bill has 38 Senate cosponsors, short of the 60 needed to overcome filibuster.

Alternatively, Congress could enact narrow fixes addressing specific Supreme Court concerns. The SAFE Banking Act would protect financial institutions serving state-legal businesses. The CLAIM Act would eliminate 280E for state-compliant operators. The STATES Act would exempt state-legal activity from federal enforcement. These incremental approaches have broader support but leave fundamental tensions unresolved.

Further Reading

• Gonzales v. Raich, 545 U.S. 1 (2005) — full Supreme Court opinion: https://supreme.justia.com/cases/federal/us/545/1/
• Controlled Substances Act, 21 U.S.C. § 801 et seq. — full statutory text: https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• Internal Revenue Code Section 280E — full text and legislative history: https://www.law.cornell.edu/uscode/text/26/280E
• DEA Notice of Proposed Rulemaking on rescheduling (May 2024): https://www.federalregister.gov/documents/2024/05/21/2024-10569/schedules-of-controlled-substances-rescheduling-of-marijuana
• National Conference of State Legislatures cannabis law database: https://www.ncsl.org/health/state-medical-cannabis-laws
• Congressional Research Service, "Marijuana: Medical and Retail—Selected Legal Issues" (updated 2026): https://crsreports.congress.gov/product/pdf/R/R44782
• Vanderbilt Law Review, "Cooperative Federalism and Marijuana Regulation" by Robert Mikos (2025): https://www.vanderbiltlawreview.org
• Supreme Court docket and case filings: https://www.supremecourt.gov/docket/docket.aspx
• American Bar Association Section on Taxation, Cannabis Tax Committee resources: https://www.americanbar.org/groups/taxation/
• Brookings Institution, "The Cannabis Industry and Federal Policy" report series: https://www.brookings.edu/topic/cannabis/